89Bio is a privately held biopharmaceutical company building a pipeline of biologic and small molecule treatments for liver and metabolic disorders. The company's lead product candidate for the treatment of NASH is BIO89-100. Currently in Phase 1, BIO89-100 is a novel long-acting glycopegylated FGF21 analogue.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/25/18 | $60,000,000 | Series A |
Longitude Capital OrbiMed Israel  OrbiMed US Pontifax RA Capital Management | undisclosed |
